## CLAIMS

## What is claimed is:

- A composition comprising an isolated polynucleotide encoding a protein having TNF-R1-DD ligand protein activity.
- The composition of claim 1 wherein said polynucleotide is selected from the group consisting of:
  - (a) a polynucleotide comprising the nucleotide sequence of SEQ ID
     NO:1 from nucleotide 2 to nucleotide 1231;
  - (b) a polynucleotide comprising a fragment of the nucleotide sequence of SEQ ID NO:1;
  - (c) a polynucleotide encoding an TNF-R1-DD ligand protein comprising the amino acid sequence of SEQ ID NO:2;
  - (d) a polynucleotide encoding an TNF-R1-DD ligand protein comprising a fragment of the amino acid sequence of SEQ ID NO:2; and
  - (e) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(d).
  - The composition of claim 1 wherein said polynucleotide sequence is selected from the group consisting of:
    - (a) a polynucleotide comprising the nucleotide sequence of SEQ ID
       NO:3 from nucleotide 2 to nucleotide 415;
    - (b) a polynucleotide comprising a fragment of the nucleotide sequence of SEQ ID NO:3;
    - (c) a polynucleotide encoding an TNF-R1-DD ligand protein comprising the amino acid sequence of SEQ ID NO:4;
    - (d) a polynucleotide encoding an TNF-R1-DD ligand protein comprising a fragment of the amino acid sequence of SEQ ID NO:4; and
    - (e) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(d).

30

10

15

20

5	4.	A composition of claim I wherein said	polynucleotide is operably linked
	to an express	ion control sequence.	•

- 5. A host cell transformed with a composition of claim 4.
- The host cell of claim 5, wherein said cell is a mammalian cell.
  - 7. A process for producing an TNF-R1-DD ligand protein, which comprises:
    - (a) growing a culture of the host cell of claim 5 in a suitable culture medium: and
      - (b) purifying the TNF-R1-DD ligand protein from the culture.
  - A composition comprising a protein having TNF-R1-DD ligand protein activity.

- 9. The composition of claim 8 wherein said protein comprises an amino acid sequence selected from the group consisting of:
  - (a) the amino acid sequence of SEO ID NO:2; and
  - (b) fragments of the amino acid sequence of SEQ ID NO:2;
- 25 said protein being substantially free from other mammalian proteins.
  - 10. The composition of claim 8 wherein said protein comprises an amino acid sequence selected from the group consisting of:
    - (a) the amino acid sequence of SEQ ID NO:4; and
- 30 (b) fragments of the amino acid sequence of SEQ ID NO:4; said protein being substantially free from other mammalian proteins.
  - 11. The composition of claim 8 wherein said protein comprises an amino acid sequence selected from the group consisting of:
- 35 (a) the amino acid sequence of SEQ ID NO:6; and
  - (b) fragments of the amino acid sequence of SEQ ID NO:6;

15

20

25

- 5 said protein being substantially free from other mammalian proteins.
  - The composition of claim 8, further comprising a pharmaceutically acceptable carrier.
  - A composition comprising an antibody which specifically reacts with the TNF-R1-DD ligand protein of claim 8.
    - A method of identifying an inhibitor of TNF-R death domain binding which comprises:
      - (a) combining an TNF-R death domain protein with a composition of claim 8, said combination forming a first binding mixture;
        - (b) measuring the amount of binding between the TNF-R death domain protein and the TNF-R1-DD ligand protein in the first binding mixture;
        - (c) combining a compound with the TNF-R death domain protein and an TNF-R1-DD ligand protein to form a second binding mixture;
        - (d) measuring the amount of binding in the second binding mixture; and
        - (e) comparing the amount of binding in the first binding mixture with the amount of binding in the second binding mixture:
  - wherein the compound is capable of inhibiting TNF-R death domain binding when a decrease in the amount of binding of the second binding mixture occurs.
  - 15. The method of claim 14 wherein said TNF-R1-DD ligand protein comprises an amino acid sequence selected from the group consisting of:
    - (a) the amino acid sequence of SEQ ID NO:2;
      - (b) fragments of the amino acid sequence of SEQ ID NO:2;
      - (c) the amino acid sequence of SEO ID NO:4:

. /	-

- (d) fragments of the amino acid sequence of SEQ ID NO:4;
  - (e) the amino acid sequence of SEQ ID NO:6;
  - (f) fragments of the amino acid sequence of SEQ ID NO:6;
  - (g) the amino acid sequence of SEQ ID NO:8; and
  - (h) fragments of the amino acid sequence of SEQ ID NO:8.

5

- 16. A method of preventing or ameliorating an inflammatory condition which comprises administering a therapeutically effective amount of a composition of claim 12.
- TNF-R1-DD ligand protein produced according to the method of claim
  - A method of inhibiting TNF-R death domain binding comprising administering a therapeutically effective amount of a composition of claim 12.

20

25

30

- 19. A method of preventing or ameliorating an inflammatory condition which comprises administering to a mammalian subject a therapeutically effective amount of a composition comprising a pharmaceutically acceptable carrier and a protein selected from the group consisting of IGFBP-5 and fragments thereof having TNF-R1-DD ligand protein activity.
- 20. A method of inhibiting TNF-R death domain binding comprising administering to a mammalian subject a therapeutically effective amount of a composition comprising a pharmaceutically acceptable carrier and a protein selected from the group consisting of IGFBP-5 and fragments thereof having TNF-R1-DD ligand protein activity.
- A composition comprising an inhibitor identified according to the method of claim 14.

15

20

25

- 5 22. The composition of claim 21 further comprising a pharmaceutically acceptable carrier.
  - 23. A method of preventing or ameliorating an inflammatory condition comprising administering to a mammalian subject a therapeutically effective amount of the composition of claim 22.
    - 24. A method of inhibiting TNF-R death domain binding comprising administering to a mammalian subject a therapeutically effective amount of the composition of claim 22.
  - 25. A composition comprising a pharmaceutically acceptable carrier and a protein selected from the group consisting of IGFBP-5 and fragments thereof having TNF-R1-DD ligand protein activity.
  - 26. A method of identifying an inhibitor of TNF-R death domain binding which comprises:
    - (a) transforming a cell with a first polynucleotide encoding an TNF-R death domain protein, a second polynucleotide encoding an TNF-R1-DD ligand protein, and at least one reporter gene, wherein the expression of the reporter gene is regulated by the binding of the TNF-R1-DD ligand protein encoded by the second polynucleotide to the TNF-R death domain protein encoded by the first polynucleotide;
    - $\begin{tabular}{ll} (b) & & growing the cell in the presence of and in the absence of a compound; and \\ \end{tabular}$
    - (c) comparing the degree of expression of the reporter gene in the presence of and in the absence of the compound;
      wherein the compound is capable of inhibiting TNF-R death domain binding when a decrease in the degree of expression of the reporter gene occurs.
- 35 27. The method of claim 26 wherein the second polynucleotide is selected from the group consisting of:

30

35

	)	)					
5	(a)	a polynucleotide comprising the nucleotide sequence of SEQ ID					
	NO:1 from nu	eleotide 2 to nucleotide 1231;					
	(b)	a polynucleotide comprising a fragment of the nucleotide					
	sequence of SI	Q ID NO:1, which encodes a protein having TNF-R1-DD ligand					
	protein activity	-					
10	(c)	a polynucleotide encoding an TNF-R1-DD ligand protein					
	comprising the	amino acid sequence of SEQ ID NO:2;					
	(d)	a polynucleotide encoding an TNF-R1-DD ligand protein					
	comprising a fragment of the amino acid sequence of SEQ ID NO:2 and having $$						
	TNF-R1-DD I	igand protein activity;					
15	(e)	a polynucleotide comprising the nucleotide sequence of SEQ ID					
	NO:3 from nucleotide 2 to nucleotide 415;						
	(f)	a polynucleotide comprising a fragment of the nucleotide					
	sequence of SEQ ID NO:3, which encodes a protein having TNF-R1-DD liga						
	protein activit	y;					
20	(g)	a polynucleotide encoding an TNF-R1-DD ligand protein					
	comprising the	e amino acid sequence of SEQ ID NO:4;					
	(h)	a polynucleotide encoding an TNF-R1-DD ligand protein					
	comprising a f	ragment of the amino acid sequence of SEQ ID NO:4 and having					
	TNF-R1-DD l	igand protein activity;					

NO:5 from nucleotide 2 to nucleotide 559;

protein activity:

a polynucleotide encoding an TNF-R1-DD ligand protein comprising the amino acid sequence of SEQ ID NO:6; a polynucleotide encoding an TNF-R1-DD ligand protein (l) comprising a fragment of the amino acid sequence of SEQ ID NO:6 and having TNF-R1-DD ligand protein activity; a polynucleotide comprising the nucleotide sequence of SEO ID NO:7 from nucleotide 57 to nucleotide 875;

sequence of SEQ ID NO:5, which encodes a protein having TNF-R1-DD ligand

a polynucleotide comprising the nucleotide sequence of SEQ ID

a polynucleotide comprising a fragment of the nucleotide

25

30

5	(n)	a polynucleotide	comprising a	fragment of	the nucleotide
		SEQ ID NO:7, which		_	
	protein activ	vity;	•	Ü	J
	(0)	a polynucleotide	encoding an	TNF-R1-DD	ligand proteir
	comprising	the amino acid seque	nce of SEQ ID	NO:8;	•
.0	(p)	a polynucleotide	encoding an	TNF-R1-DD	ligand proteir
	comprising a	a fragment of the amir	no acid sequend	e of SEQ ID N	O:8 and having

TNF-R1-DD ligand protein activity; and

- (q) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(p), which encodes a protein having TNF-R1-DD ligand protein activity.
- 28. The method of claim 26 wherein the cell is a yeast cell.
- 29. The composition of claim 1 wherein said polynucleotide sequence is
   selected from the group consisting of:
  - (a) a polynucleotide comprising the nucleotide sequence of SEQ ID
     NO:9 from nucleotide 2 to nucleotide 931;
  - (b) a polynucleotide comprising a fragment of the nucleotide sequence of SEQ ID NO:9;
  - (c) a polynucleotide encoding an TNF-R1-DD ligand protein comprising the amino acid sequence of SEQ ID NO:10;
  - (d) a polynucleotide encoding an TNF-R1-DD ligand protein comprising a fragment of the amino acid sequence of SEQ ID NO:10; and
  - (e) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(d).
  - 30. The composition of claim 1 wherein said polynucleotide sequence is selected from the group consisting of:
- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID
   NO:11 from nucleotide 2 to nucleotide 1822;

25

30

5		(b)	a	polynucleotide	comprising	a	fragment	of	the	nucleotide
	segueno	e of S	=0	ID NO-11-						

- (c) a polynucleotide encoding an TNF-R1-DD ligand protein comprising the amino acid sequence of SEQ ID NO:12;
- (d) a polynucleotide encoding an TNF-R1-DD ligand protein comprising a fragment of the amino acid sequence of SEO ID NO:12: and
- (e) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(d).
- The composition of claim 8 wherein said protein comprises an amino
   acid sequence selected from the group consisting of:
  - (a) the amino acid sequence of SEO ID NO:10; and
  - (b) fragments of the amino acid sequence of SEQ ID NO:10;
     said protein being substantially free from other mammalian proteins.
- 20 32. The composition of claim 8 wherein said protein comprises an amino acid sequence selected from the group consisting of:
  - (a) the amino acid sequence of SEO ID NO:12: and
  - (b) fragments of the amino acid sequence of SEQ ID NO:12; said protein being substantially free from other mammalian proteins.

33. The method of claim 14 wherein said TNF-R1-DD ligand protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:10;
- (b) fragments of the amino acid sequence of SEQ ID NO:10;
- (c) the amino acid sequence of SEQ ID NO:12; and
- (d) fragments of the amino acid sequence of SEQ ID NO: F2.
- $34. \hspace{0.5cm} \mbox{The method of claim 26 wherein the second polynucleotide is selected} \\ \mbox{from the group consisting of:} \\$
- 35 (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:9 from nucleotide 2 to nucleotide 931:

5 a polynucleotide comprising a fragment of the nucleotide sequence of SEQ ID NO:9, which encodes a protein having TNF-R1-DD ligand protein activity: a polynucleotide encoding an TNF-R1-DD ligand protein (c) comprising the amino acid sequence of SEQ ID NO:10; 10 a polynucleotide encoding an TNF-R1-DD ligand protein comprising a fragment of the amino acid sequence of SEQ ID NO:10 and having TNF-R1-DD ligand protein activity; a polynucleotide comprising the nucleotide sequence of SEQ ID (e) NO:11 from nucleotide 2 to nucleotide 1822: 15 a polynucleotide comprising a fragment of the nucleotide sequence of SEQ ID NO:11, which encodes a protein having TNF-R1-DD ligand protein activity: a polynucleotide encoding an TNF-R1-DD ligand protein comprising the amino acid sequence of SEQ ID NO:12; and 20 a polynucleotide encoding an TNF-R1-DD ligand protein comprising a fragment of the amino acid sequence of SEQ ID NO:12 and having TNF-R1-DD ligand protein activity; and a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(h), which encodes 25 a protein having TNF-R1-DD ligand protein activity. The composition of claim I wherein said polynucleotide sequence is selected from the group consisting of: a polynucleotide comprising the nucleotide sequence of SEQ ID NO:13 from nucleotide 3 to nucleotide 2846; 30

comprising the amino acid sequence of SEQ ID NO:14;

sequence of SEO ID NO:13:

35

a polynucleotide comprising a fragment of the nucleotide

a polynucleotide encoding an TNF-R1-DD ligand protein

a polynucleotide encoding an TNF-R1-DD ligand protein

25

- 5 (e) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(d).
  - 36. The composition of claim 8 wherein said protein comprises an amino acid sequence selected from the group consisting of:
    - (a) the amino acid sequence of SEQ ID NO:14; and
  - (b) fragments of the amino acid sequence of SEQ ID NO:14;said protein being substantially free from other mammalian proteins.
- 37. The method of claim 14 wherein said TNF-R1-DD ligand protein comprises an amino acid sequence selected from the group consisting of:
  - (a) the amino acid sequence of SEQ ID NO:14; and
  - (b) fragments of the amino acid sequence of SEQ ID NO:14.
- 38. The method of claim 26 wherein the second polynucleotide is selected 20 from the group consisting of:
  - (a) a polynucleotide comprising the nucleotide sequence of SEQ ID
     NO:13 from nucleotide 3 to nucleotide 2846;
  - (b) a polynucleotide comprising a fragment of the nucleotide sequence of SEQ ID NO:13, which encodes a protein having TNF-R1-DD ligand protein activity;
  - (c) a polynucleotide encoding an TNF-R1-DD ligand protein comprising the amino acid sequence of SEQ ID NO:14;
  - (d) a polynucleotide encoding an TNF-R1-DD ligand protein comprising a fragment of the amino acid sequence of SEQ ID NO:14 and having TNF-R1-DD ligand protein activity; and
  - (e) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(d), which encodes a protein having TNF-R1-DD ligand protein activity.
- 35 39. The composition of claim 1 wherein said polynucleotide sequence is selected from the group consisting of:

15

25

30

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID
   NO:15 from nucleotide 326 to nucleotide 5092:
  - (b) a polynucleotide comprising a fragment of the nucleotide sequence of SEO ID NO:15:
  - (c) a polynucleotide encoding an TNF-R1-DD ligand protein comprising the amino acid sequence of SEQ ID NO:16;
  - (d) a polynucleotide encoding an TNF-Ri-DD ligand protein comprising a fragment of the amino acid sequence of SEQ ID NO:16; and
  - (e) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(d).
  - 40. The composition of claim 8 wherein said protein comprises an amino acid sequence selected from the group consisting of:
    - (a) the amino acid sequence of SEQ ID NO:16; and
- (b) fragments of the amino acid sequence of SEQ ID NO:16;
   said protein being substantially free from other mammalian proteins.
  - 41. The method of claim 14 wherein said TNF-R1-DD ligand protein comprises an amino acid sequence selected from the group consisting of:
    - (a) the amino acid sequence of SEQ ID NO:16; and
    - (b) fragments of the amino acid sequence of SEQ ID NO:16.
    - 42. The method of claim 26 wherein the second polynucleotide is selected from the group consisting of:
      - (a) a polynucleotide comprising the nucleotide sequence of SEQ ID
         NO:15 from nucleotide 326 to nucleotide 5092;
      - (b) a polynucleotide comprising a fragment of the nucleotide sequence of SEQ ID NO:15, which encodes a protein having TNF-R1-DD ligand protein activity;
      - (c) a polynucleotide encoding an TNF-R1-DD ligand protein comprising the amino acid sequence of SEQ ID NO:16;

- 5 (d) a polynucleotide encoding an TNF-R1-DD ligand protein comprising a fragment of the amino acid sequence of SEQ ID NO:16 and having TNF-R1-DD ligand protein activity; and
  - (e) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(d), which encodes a protein having TNF-R1-DD ligand protein activity.
  - 43. The composition of claim 1 wherein said polynucleotide sequence is selected from the group consisting of:
    - (a) a polynucleotide comprising the nucleotide sequence of SEQ ID
       NO:17 from nucleotide 14 to nucleotide 2404;
    - (b) a polynucleotide comprising a fragment of the nucleotide sequence of SEQ ID NO:17;
    - $\label{eq:continuous} (c) \qquad a \ \ polynucleotide \ encoding \ an \ \ TNF-R1-DD \ \ ligand \ \ protein \\ comprising the amino acid sequence of SEQ ID NO:18;$
    - (d) a polynucleotide encoding an TNF-R1-DD ligand protein comprising a fragment of the amino acid sequence of SEQ ID NO:18; and
    - $\mbox{(e)} \qquad \mbox{a polynucleotide capable of hybridizing under stringent} \\ \mbox{conditions to any one of the polynucleotides specified in (a)-(d).}$
  - 44. The composition of claim 8 wherein said protein comprises an amino acid sequence selected from the group consisting of:
    - (a) the amino acid sequence of SEQ ID NO:18; and
    - $(b) \qquad \text{fragments of the amino acid sequence of SEQ ID NO:} 18; \\ \text{said protein being substantially free from other mammalian proteins.}$
    - 45. The method of claim 14 wherein said TNF-R1-DD ligand protein comprises an amino acid sequence selected from the group consisting of:
      - (a) the amino acid sequence of SEQ ID NO:18; and
      - (b) fragments of the amino acid sequence of SEQ ID NO:18.

10

15

20

25

- 5 46. The method of claim 26 wherein the second polynucleotide is selected from the group consisting of:
  - (a) a polynucleotide comprising the nucleotide sequence of SEQ ID
     NO:17 from nucleotide 14 to nucleotide 2404;
  - (b) a polynucleotide comprising a fragment of the nucleotide sequence of SEQ ID NO:17, which encodes a protein having TNF-R1-DD ligand protein activity;
  - (c) a polynucleotide encoding an TNF-R1-DD ligand protein comprising the amino acid sequence of SEQ ID NO:18;
  - (d) a polynucleotide encoding an TNF-R1-DD ligand protein comprising a fragment of the amino acid sequence of SEQ ID NO:18 and having TNF-R1-DD ligand protein activity; and
  - (e) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(d), which encodes a protein having TNF-R1-DD ligand protein activity.